Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury

American Journal of Medicine

Volumn 104, Issue 3 A, 1998, Pages

  Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; SALSALATE; SUCRALFATE; TOLMETIN;

AGE; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; DISEASE PREDISPOSITION; DRUG COST; DRUG INDUCED DISEASE; DYSPEPSIA; EPIGASTRIC PAIN; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HUMAN; HYPERTENSION; INDIGESTION; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; OSTEOARTHRITIS; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; ULCER PERFORATION;

EID: 0032579890     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00207-6     Document Type: Conference Paper

References (92)

1. Anon. Anti-arthritis medication usage: United States 1991. Stat Bull Metrop Insur Co. 1992;73:25-34.
2. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114: 257-263.
3. Chrischilles EA, Lemke JH, Wallace RB, Drube GA. Prevalence and characteristics of multiple analgesic drug use in an elderly study group. J Am Geriatr Soc. 1990;38:979-984.
4. Stewart RB, Hale WE, Marks RG. Analgesic drug use in an ambulatory elderly population. Drug Intell Clin Pharmacol. 1982;16:833-836.
5. Gutthann SP, García Rodríguez LA, Raiford DS. Individual non-steroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in Saskatchewan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
6. Somerville K, Faulkner G, Langmen M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986;1:462-464.
7. Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer compliations with nonsteroidal antiinflammatory drug thrapy. Arthritis Rheum. 1993;36:84-90.
8. Hogan DB, Campbell NRC, Crutcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J. 1994;151:315-322.
9. Ray WA, Griffin MR, Shorr RI. Adverse drug reactions and the elderly. Health Aff (Millwood). 1990;9:114-122.
10. Smalley WE, Ray WA, Daugherty J, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539-545.
11. Henry D, Lim LL-Y, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563-1566.
12. Gabriel SE, Jaakkimainen RL, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787-796.
13. Bollini P, García Rodríguez LA, Gutthann SP, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992;152:1289-1295.
14. Griffin MR, Ray WA, Schaffner W. Nonstroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109:359-363.
15. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
16. Henry D, Dobson A, Turner C, et al. NSAIDs and risk of upper gastrointestinal bleeding. Lancet. 1991;337:730.
17. Laporte J, Carné X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and nonsteroidal anti-inflammatory drugs. Lancet. 1991;337:85-89.
18. Sander JWAS, Shorvon SD. Non-steroidal anti-inflammatory drugs - prescribe with caution. J R Coll Gen Pract. 1988;38:49-52.
19. Brandt KD. Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs? Rheum Dis Clin North Am. 1993;19:697-712.
20. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol. 1988;41:35-45.
21. García Rodríguez LA, Walker AM, Gutthann SP. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology. 1992;3:337-342.
22. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life: results of a randomised trial. Br J Clin Pharmacol. 1989;27:235-242.
23. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs for gastrointestinal disease among nonsteroidal anti-inflammatory drug users. J Gen Intern Med. 1996;11:461-469.
24. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153-1158.
25. Shallcross TM, Heatley RV. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ. 1990; 300:368-369.
26. Dieppe PA, Frankel SJ, Toth B. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected? Lancet. 1993;341:353-354.
27. Liang MH, Fortin P. Management of osteoarthritis of the hip and knee. N Engl J Med. 1991;325:125-127.
28. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
29. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-222.
30. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
31. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med. 1989;31: 129-135.
32. Schöön IM, Melström D, Oden A, Ytterberg BO. Incidence of peptic ulcer disease in Gothenburg, 1985. BMJ. 1989; 299:1131-1134.
33. Henry D, Robertson J. Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. Gastroenterology. 1993;104:1083-1091.
34. Graves EJ, Kozak LJ. National Hospital Discharge Survey: annual summary, 1990. National Center for Health Statistics. Vital Health Stat. 1992;13:1-51.
35. Lanza FL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. Arch Intern Med. 1995;155:1371-1377.
36. Borody TJ, Brandi S, Andrews P, et al. Helicobacter pylori-negative gastric ulder. Am J Gastroenterol. 1992;87:1403-1406.
37. Borody TS, George LL, Brandi S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol. 1991;86: 1154-1157.
38. Nensey YM, Schubert TT, Bologna SD, Ma CK. Helicobacter pylori-negative duodenal ulder. Am J Med. 1991;91: 15-18.
39. Loeb DS, Talley NJ, Ahlquist DA, et al.Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology. 1992;102:1899-1905.
40. Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991;100:1653-1657.
41. Martin DF, Montgomery E, Dobek AS, et al. Campylobacter pylori, NSAIDs, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol. 1989;84:1268-1272.
42. Cardon JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987;147:1054-1059.
43. Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med. 1974;290:469-473.
44. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:1019-1022.
45. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum. 1993;36:447-457.
46. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41-47.
47. Hillman A, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
48. Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J. 1990;66:639-646.
49. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritis patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique. 1990;38:187-199.
50. de Pouvourville G. The Economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol. 1992;96(suppl):49-53.
51. Graves EJ. Detailed diagnoses and procedures. National Hospital Discharge Survey, 1989. National Center for Health Statistics. Vital Health Stat. 1991;13:1-236.
52. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol. 1992;19:604-607.
53. Tomita DK, Kennedy DL, Baum C, et al. Drug utilization in the United States: 1988 tenth annual review. Department of Health and Human Services, 1989.
54. Tomita DK, Baum C, Kennedy DL, et al. Drug utilization in the United States: 1987 ninth annual review. Department of Health and Human Services, 1988.
55. Bjarnason I, Zanelli G, Prouse P, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987;11:711-714.
56. Matsuhashi N, Yamada A, Hiraishi M, et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol. 1992; 87:1183-1186.
57. Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc. 1995;70:55-61.
58. Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and hemorrhage. BMJ. 1985;290:347-349.
59. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1984;310: 563-572.
60. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. Ann Intern Med. 1990;112:568-576.
61. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med. 1990;112:559-560.
62. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991; 31:588-598.
63. Brater DC, Anderson S, Baird B, Campbell W. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985;27:66-73.
64. Brater DC, Anderson SA, Brown-Cartwright D, Toto RD. Effects of nonsteroidal anti-inflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis. 1986;5:351-355.
65. Brater DC. Clinical aspects of renal prostaglandins and NSAID therapy. Semin Arthritis Rheum. 1988;17:17-22.
66. Kleinknecht D, Landis P, Goldfarb B. Analgesic and nonsteroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol. 1986;25:275-281.
67. Stilman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity: should we be concerned? Arch Intern Med. 1990;150:568-570.
68. Smith MC, Dunn MJ. The role of prostaglandins in human hypertension. The National Kidney Foundation. 1985;5: A32-A39.
69. Wong DG, Spence JD, Lamki L, et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet. 1986;1:997-1001.
70. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. Ann Intern Med. 1987;107:628-635.
71. Chrischilles EA, Wallace RB. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol. 1993;48:M91-M96.
72. Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol. 1993;35:455-459.
73. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
74. Radack K, Deck C. Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients? J Gen Intern Med. 1987;2:108-112.
75. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
76. Gay GR. Another side effect of NSAIDs. JAMA. 1990;264: 2677-2678.
77. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
78. Brooks PM, Day RO. Drug therapy. N Engl J Med. 1991; 324:1716-1725.
79. Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol. 1993;32:595-600.
80. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993; 36:1196-1206.
81. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325: 87-91.
82. Amadio P Jr, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res. 1983;34:59-66.
83. Puett DW, Griffin MR. Published trials of nonmedicinal and noninvasive therapies for hip and knee osteoarthritis. Ann Intern Med. 1994;121:133-140.
84. Jones AC, Berman P, Doherty M. Non-steroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol. 1992;31:45-48.
85. Swift GL, Rhodes J. Are non-steroidal anti-inflammatory drugs always necessary? A general practice survey. Br J Clin Pract. 1992;46:92-94.
86. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol. 1992;47:M111-M115.
87. Kjaersgaard-Andersen P, Naefei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. Pain. 1990;43:309-318.
88. Griffin MR, Brandt KD, Liang MH, et al. Practical management of osteoarthritis: integration of pharmacologic and nonpharmacologic measures. Arch Fam Med. 1995;4: 1049-1055.
89. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1991;34:1353-1360.
90. Barradell LB, Whittington R, Benfield P. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. Pharmacoeconomics. 1993;3:140-170.
91. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
92. Gabriel SE, Campion ME, O'Fallon M. Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol. 1993;20:358-361.